toxylact: a03cb03 atropin & psycholeptics

The first professional lActological database in the word

This web page–style monograph summarizes toxicological and lactation‑related aspects of medicines classified in ATC group A03CB03 (atropine and psycholeptics) for professional use.medpedia.framar

ATC group and constituents

ATC A03CB03 comprises fixed combinations of atropine (a belladonna‑derived antimuscarinic alkaloid) with psycholeptic agents used for functional gastrointestinal disorders. Atropine provides spasmolytic and antisecretory effects, while psycholeptics (typically sedative/anxiolytic drugs) contribute central nervous system (CNS) calming and modulation of visceral pain perception.medpedia.framar

Indications and clinical use

Atropine–psycholeptic combinations are employed in the management of bradycardia and conduction disturbances, for premedication before surgery to reduce respiratory tract secretions, and as part of antidotal regimens in poisoning with organophosphorus insecticides, certain mushrooms and carbamates. In gastroenterology, they are used for symptomatic treatment of painful functional spasms and hypermotility in the gastrointestinal tract when a psychovegetative component is present.medpedia.framar

Mechanism of action (pharmacodynamics)

Atropine acts as a competitive antagonist at muscarinic (M‑cholinergic) receptors, thereby inhibiting parasympathetic transmission from postganglionic cholinergic nerves to effector organs such as the heart, smooth muscle and exocrine glands. The psycholeptic component exerts CNS depressant or tranquilizing effects, decreasing anxiety, autonomic hyperreactivity and central perception of visceral discomfort.medpedia.framar

Toxicological profile – atropine

Atropine toxicity is dominated by antimuscarinic effects, with dose‑dependent central and peripheral manifestations. Reported adverse reactions include confusion, dizziness, irritability, weakness, hallucinations, headache, somnolence, insomnia, agitation, seizures, mydriasis, photophobia, and increased intraocular pressure. Cardiovascular toxicity can present as bradycardia, tachycardia and various arrhythmias, particularly in predisposed patients or in overdose.medpedia.framar

Toxicological profile – psycholeptics

Psycholeptic agents in these combinations add CNS adverse effects such as excessive sedation or, paradoxically, agitation, insomnia and seizures in susceptible individuals. When combined with atropine, overlapping CNS effects (confusion, drowsiness, hallucinations) increase the risk of impaired consciousness, falls and complex psychomotor disturbances, especially in the elderly.medpedia.framar

Contraindications and high‑risk populations

Use is contraindicated in patients with hypersensitivity to atropine or any psycholeptic co‑medication, in urinary retention and in glaucoma due to the risk of precipitating acute angle‑closure through mydriasis and raised intraocular pressure. The product information explicitly lists breastfeeding as a contraindication, reflecting safety concerns in lactating women.medpedia.framar

Lactation safety considerations

Atropine crosses into breast milk and can potentially cause anticholinergic toxicity in the breastfed infant, including feeding difficulties, constipation, tachycardia and CNS effects, particularly in neonates and premature infants. Psycholeptics may also be excreted in human milk, with possible infant sedation, poor suckling, respiratory depression or neurodevelopmental concerns depending on substance and dose; therefore, the combination A03CB03 is generally considered unsuitable during breastfeeding.medpedia.framar

Clinical recommendations in breastfeeding

Given the contraindication for use during lactation and the potential for serious anticholinergic and CNS effects in infants, these medicines should be avoided in breastfeeding women unless there is a compelling, life‑saving indication. If atropine–psycholeptic therapy is deemed unavoidable (e.g. emergency antidotal use), temporary interruption of breastfeeding, close clinical monitoring of the infant, and consideration of alternative feeding strategies are recommended.medpedia.framar

Risk mitigation and monitoring

Before prescribing A03CB03 combinations, clinicians should screen for glaucoma, urinary retention, significant cardiovascular disease, seizure disorders and psychiatric comorbidities. During treatment, monitoring for changes in mental status, visual symptoms, cardiac rhythm, sleep disturbance and signs of autonomic dysfunction helps detect early toxicity, especially in elderly or polymorbid patients.medpedia.framar

Dosage and access

The summary information emphasizes that the dosage regimen must be individualized and determined by a physician, with prior consultation recommended for all patients. Access to medicines in ATC group A03CB03 is restricted by prescription, reflecting their potency, toxicity profile and contraindication in sensitive populations such as breastfeeding women.medpedia.framar

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.